Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02303444 · ClinicalTrials.gov registry record
An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
A clinical trial of Thyroid Neoplasms, sponsored by Bayer.
- Completed
- Registry status
- 667
- Enrollment target
- 20
- Study locations
NCT02303444: Completed study of Thyroid Neoplasms, sponsored by Bayer.
NCT02303444 is a study of Thyroid Neoplasms that has completed, run by Bayer. The registered enrollment target is 667 participants, below the 744-participant average among 7 other Thyroid Neoplasms trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02303444, a study of Thyroid Neoplasms, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 667 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.
Primary Outcome
TTSP is defined as the time interval from the day of study entry to the date of first symptomatic progression. Patients who do not have a symptomatic progression at the time of analysis will be censored at the date of their last evaluable assessment.
Conditions Studied
Interventions
- DRUG Sorafenib (Nexavar, BAY43-9006)
- DRUG Other Multikinase inhibitors
Study Locations (20)
Other
- - Multiple Locations
- - Multiple Locations
- - Multiple Locations
- - Multiple Locations
California
- - Los Angeles
- - Torrance
Alabama
- - Birmingham
Colorado
- - Aurora
District of Columbia
- - Washington D.C.
Florida
- - Plantation
Georgia
- - Atlanta
Hawaii
- - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 667 participants |
| Start Date | 2015-04-08 |
| Est. Completion | 2020-07-24 |
What the finished NCT02303444 record still lists
NCT02303444 is an observational study that tracks outcomes without assigning an intervention. The registered 667 participants enrollment target is mid-sized for trials with a published cap, below the 744-participant average among 7 other Thyroid Neoplasms trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Thyroid Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib (Nexavar, BAY43-9006) is the first listed.
NCT02303444 names 20 study sites across 16 states, led by Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT02303444 about?
NCT02303444 is a clinical study titled "An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors". The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.
What is the current status of trial NCT02303444?
This trial is currently completed. The enrollment target is 667 participants. The study started on 2015-04-08. Estimated completion is 2020-07-24.
What conditions does trial NCT02303444 study?
This clinical trial studies the following conditions: Thyroid Neoplasms.
What interventions are being tested in trial NCT02303444?
The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) (DRUG), Other Multikinase inhibitors (DRUG).
Who is sponsoring clinical trial NCT02303444?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02303444 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients
RECRUITING · NA
-
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
RECRUITING
-
TRAIL Study: Feasibility and Pilot
RECRUITING · NA
-
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RECRUITING
-
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 1
-
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04155034 · 668 participants · Phase 3
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
- NCT04179981 · 668 participants · NA
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
- NCT05006482 · 668 participants · Phase 3
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI